#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Search results: (10000)



News Iron Deficiency and Administration of Ferric Carboxymaltose in Patients with Heart Failure

Iron deficiency is very common in patients with heart failure and is associated with exercise intolerance, reduced quality of life, increased mortality, and higher risk of hospitalization, regardless of the presence of anemia. Clinical studies have previously demonstrated the positive effect of intravenous administration of ferric carboxymaltose (FCM) in patients with chronic heart failure with reduced ejection fraction of the left ventricle. The AFFIRM-AHF study investigated the effect of FCM administration initiated shortly before discharge from hospitalization for acute heart failure.
Source: Iron Deficiency and Anemia 21. 6. 2022

News CASE STUDY: Rocker who can enjoy life again thanks to DM2 compensation p.o. semaglutide and better lifestyle

Diabetologist MUDr. Lucie Radovnická from Masaryk Hospital in Ústí nad Labem illustrates the case of her patient −⁠ a sympathetic rocker who enjoys life including concerts, beer, and good food −⁠ demonstrating how modern antidiabetic treatment with oral semaglutide in combination with thorough lifestyle re-education can achieve very good diabetes compensation and overall health improvement. One of the many benefits of this modality was the possibility to discontinue sulfonylurea derivative medication, which previously caused severe hypoglycemia.
Source: Modern Treatment of Diabetes with GLP-1 Analogues 18. 6. 2024

News Benefits of Time-Limited CLL Therapy

The advent of new targeted molecules has significantly influenced the possibilities of therapy for chronic lymphocytic leukemia (CLL) and are now an integral part of treatment regimens, including the 1st line. Individual therapeutic approaches and strategies based on them have their advantages and disadvantages as well as their target patient group, but the concept of time-limited treatment is increasingly gaining ground. Therapy today is significantly individualized, and its optimal choice is based on the assessment of various circumstances on the patient’s part and their disease.
Source: Chronic Lymphocytic Leukemia 5. 3. 2024

News Effect of Denosumab and Zoledronic Acid on Overall Survival in Patients with Metastatic Lung Cancer

In 30-40% of patients with non-small cell lung cancer (NSCLC), bone metastases develop during the course of the disease, causing so-called skeletal-related events (SREs). These events cause pain, increase morbidity, and reduce quality of life and mobility in patients. Antiresorptive agents, such as the bisphosphonate zoledronic acid or the osteoclast maturation and differentiation inhibitor denosumab, are used to prevent the occurrence of SREs. An exploratory analysis compared the effect of administering denosumab and zoledronic acid on the survival of patients with metastatic disease.
Source: Prevention of Bone Events 12. 9. 2022

News Efficacy and Safety of an Activated FXII Inhibitor in Preventing HAE Attacks

Hereditary angioedema (HAE) is a rare, potentially life-threatening inherited disorder characterized by dysregulation of the kallikrein-kinin system. This results in excessive production of bradykinin, which is responsible for soft tissue edema. Garadacimab, a human antibody inhibiting activated factor XII, is utilized in the prevention of these attacks. Its efficacy and safety were verified in a phase III clinical trial.
Source: Hereditary Angioedema 27. 4. 2023

News Adherence to Treatment of Multiple Sclerosis: How to Enhance It and What Interesting Insights Emerged from Current Research?

Therapeutic options for patients with multiple sclerosis (MS) utilizing disease-modifying drugs (DMDs) have continued to expand in recent years. However, achieving their full benefit is critically dependent on adherence to treatment. Nonadherence is demonstrably linked to an increased risk of relapses, faster progression of disability, higher treatment costs, and higher mortality. We present a summary of factors affecting adherence to treatment in MS patients, including the influence of the chosen therapy from a 2022 review and subsequent studies.
Source: Multiple Sclerosis 24. 4. 2023

News Patient with Moderate Hemophilia A and Development of FVIII Inhibitor in Old Age and Atrial Fibrillation −⁠ Interactive Case Study

MUDr. Petr Smejkal, Ph.D., from the Department of Clinical Hematology, FN Brno, has prepared a case study for you of a patient born in 1941, diagnosed with hemophilia A at around 10 years of age. In 2013, he underwent surgery for right carotid stenosis with pdFVIII substitution and was started on acetylsalicylic acid. Two weeks after discharge, subcutaneous and muscle bleeding was recognized, leading to the development of an FVIII inhibitor (high responder) with FVIII levels < 1%. Severe muscle bleeds continued approximately once every 2 months. Prophylactic treatments progressively included aPCC, pdFVIII, and emicizumab. The patient also presents with cardiovascular comorbidities: atrial fibrillation (AF) accompanied by its dilatation, diastolic heart failure, and hypertension. In 2021, he also contracted COVID-19, requiring hospitalization.
Source: Quality Life Even with Hemophilia 22. 9. 2021

News The Importance of Limosilactobacillus reuteri in Administration to Diabetics with Gingivitis

We summarize the results of a clinical study on the effect of probiotics containing Limosilactobacillus reuteri on the improvement of gingivitis in patients with diabetes. It has been proven that the supplementary administration of L. reuteri statistically significantly improves gum health and helps to suppress gingival inflammation.
Source: GI, colic and microbiome 10. 11. 2022

News How do patients perceive the treatment of ITP with romiplostim?

Romiplostim, along with eltrombopag and avatrombopag, belongs to the group of thrombopoietin receptor agonists (TPO-RA) used in the second line of treatment for immune thrombocytopenia (ITP). Its efficacy and safety are confirmed by numerous studies, but how do patients perceive its use and to what extent does it improve their quality of life? This was the focus of a review article by authors from the American Baylor College of Medicine.
Source: Immune Thrombocytopenia 15. 4. 2024

News ICIS Report: Potential of TPO-RA as Early Immunomodulatory Treatment of Immune Thrombocytopenia

The report from the meeting of the Intercontinental Cooperative ITP Study Group (ICIS) in 2022 in Lenzerheide, Switzerland, published late last year in the British Journal of Haematology, discusses the potential of early treatment of immune thrombocytopenia with thrombopoietin receptor agonists (TPO-RA) in achieving a disease remission sustainable without further therapy.
Source: Immune Thrombocytopenia 24. 1. 2024

News Less Ventricular Arrhythmias and ICD Shocks After Introduction of Sacubitril/Valsartan

Is the decrease in the incidence of sudden cardiac death among patients using sacubitril/valsartan due to a lower risk of ventricular arrhythmias? And does it have anything to do with reverse left ventricular remodeling? A newly published study utilizing data from telemonitoring of patients with implanted devices focused on this.
Source: Chronic Heart Failure and Lipidology 8. 1. 2020

News Severe Polytrauma in a Man with von Willebrand Disease −⁠ Case Report

The authors of a recently published case report present a case of multiple trauma (including brain injury) in a young man with von Willebrand disease (vWD) type 2A, in whom repeated administration of a concentrate containing von Willebrand factor (vWF) and coagulation factor VIII (FVIII) led to successful healing without neurological deficit.
Source: Von Willebrand Disease 29. 11. 2022

News How does empagliflozin perform in older type 2 diabetics compared to liraglutide and sitagliptin in terms of HHF and MACE risks?

Last fall, a study was published in JAMA Network Open, focusing on older patients with type 2 diabetes mellitus (DM2), examining the cardiovascular risk impact when treated with empagliflozin, liraglutide, or sitagliptin. Currently, there is limited evidence comparing the effectiveness of various glucose-lowering agents intended for second-line treatment in DM2 patients undergoing routine care, who have a broad spectrum of cardiorenal risks.
Source: Diabetes 28. 8. 2023

News Reducing Cardiovascular Risk in Diabetics Through Hypertension Treatment

The presence of hypertension in patients with diabetes worsens overall cardiovascular (CV) prognosis and increases the prevalence of chronic renal failure. Adequate treatment of hypertension can significantly influence the development and severity of these complications. What target blood pressure (BP) values should we aim for in diabetics, which antihypertensive therapy to choose, and why not forget about 24-hour BP monitoring?
Source: Diabetes 21. 6. 2021

News Pain Management in Patients After Hip and Knee Arthroplasty –⁠ Data from Clinical Practice

Inadequate analgesia after hip and knee arthroplasty can result in delayed postoperative recovery accompanied by chronic pain. The retrospective study presented below compared the efficacy of analgesia via continuous epidural infusion of ropivacaine, patient-controlled IV analgesia with the so-called Würzburg drip, and piritramide.
Source: Analgesia 3. 10. 2023

News Hodgkin Lymphoma in a Summary of News from Post-ASH 2021

Dr. Anna Suredová from the Clinical Hematology Department of the Catalonian Oncology Institute in Barcelona, newly elected president of the European Society for Bone Marrow Transplantation (EBMT), also remotely participated in this year's Prague Hematology Days (PHD 2022). In her lecture, she presented an overview of highlights from 4 clinical studies regarding Hodgkin lymphoma (HL) presented during the Post-ASH 2021 meeting.
Source: Hematologic Malignancies 28. 3. 2022

News IPFchecker Project Helps Detect Patients with Idiopathic Pulmonary Fibrosis

Idiopathic pulmonary fibrosis is a serious progressive disease of the lung tissue of unclear etiology. Highly effective antifibrotic therapy is used in treatment, which can significantly prolong the lives of patients. However, timely detection of the disease is necessary for treatment success. For this purpose, the IPFchecker web application has been created, which helps radiologists and pulmonologists with more accurate diagnosis and timely detection of the disease.
Source: Pulmonary Fibrosis 24. 6. 2020

News Prediction of DM2 and CVD Development Risk Based on Lipidomic Risk Determination

The incidence of type 2 diabetes mellitus (DM2) and cardiovascular diseases (CVD) is strongly influenced by lifestyle and diet. Hypertension, hypercholesterolemia, and elevated blood glucose are often detectable before the full development of disease symptoms. Similarly, changes in the representation of other less noticeable markers—plasma lipids—can also be detected.
Source: Modern Treatment of Diabetes 20. 5. 2022

News How many heart failure patients do not take adequate doses of beta-blockers even though they could?

A British study published last year investigated the proportion of heart failure patients with reduced ejection fraction (HFrEF) who do not take an adequate dose of beta-blockers (BB), despite having no contraindications to their use. The authors analyzed the mortality of these patients over 7.6 years and looked for factors associated with the prescription of suboptimal BB doses.
Source: Cardiovascular Continuum 14. 3. 2022

News Statin Therapy May Reduce Mortality in Patients Hospitalized with COVID-19

In connection with the COVID-19 pandemic, intensive research is ongoing to understand the impact of patients' chronic medication on the prognosis of the disease. A recently published Spanish study evaluated the effect of pre-existing statin therapy on the clinical outcomes of patients hospitalized with SARS-CoV-2 infection.
Source: Cardiovascular Risks 23. 3. 2021

News Prediction of Ischemic Stroke Risk in Patients with Rheumatoid Arthritis Using a Simplified Score

Ischemic strokes (iCMP) are a common cause of death or significant disability in developed countries. Patients with rheumatoid arthritis (RA) are affected by them even more frequently than the general population. A newly developed scoring system is capable of predicting the risk of iCMP in these patients.
Source: Arthritis 3. 12. 2020

News CASE STUDIES on the topic of progressing interstitial lung processes

This page serves as a hub for case studies on the topic of progressing interstitial processes. The case studies aim to provide a multidisciplinary view on the rare disease topic of IPP.
Source: Progressive Interstitial Pulmonary Processes 7. 2. 2023

News Bimekizumab vs. Adalimumab in the Treatment of Moderate to Severe Plaque Psoriasis

Bimekizumab is a humanized IgG1 monoclonal antibody that selectively inhibits interleukins 17A and 17F for the treatment of moderate to severe plaque psoriasis in adults for whom systemic therapy is indicated. The phase III BE SURE clinical trial focused on comparing the efficacy and safety of bimekizumab and the tumor necrosis factor-alpha (TNF-α) inhibitor adalimumab, which currently serves as one of the mainstays of systemic therapy.
Source: Psoriasis 12. 9. 2022

News Analysis of the Benefits and Risks of Superabsorbent Dressings in the Treatment of Moderate to Highly Exuding Leg Ulcers

A study on the benefits and risks of superabsorbent dressings compared to standard dressings in the treatment of moderate to highly exuding leg ulcers was published last year in The International Journal of Lower Extremity Wounds.
Source: Wound Healing 22. 2. 2022

News Under the Microscope: How is Patient Care for Heart Failure in the Czech Republic in Real Practice?

The journal Vnitřní lékařství recently published the results of a survey conducted among outpatient cardiologists and internists. The aim was to determine the level of diagnosis and treatment of patients with chronic heart failure (CHF) in real-life practice in the Czech Republic, with a special focus on the presence of symptoms in patients who have not yet been diagnosed. We briefly summarize the key findings from this survey.
Source: Heart Failure 18. 4. 2024

1 11 12 13 14 15 400
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#